Sign In
Buy CDNA
$22.07
-0.730 (-3.20%)
At Close: Jun 02, 2026
Bamco Inc. NY Has $45.88 Million Stake in CareDx, Inc. $CDNA
04:22am, Monday, 16'th Mar 2026
Bamco Inc. NY grew its stake in shares of CareDx, Inc. (NASDAQ: CDNA) by 29.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commiss
CareDx Introduces VANTx AI Platform for Complex Transplant Datasets
12:16pm, Thursday, 12'th Mar 2026
CDNA launches VANTx, an AI-driven cloud platform that turns complex transplant datasets into insights to support clinical research and real-world evidence.
CareDx Details Transplant+ Roadmap, AlloHeme Timeline, and 2026 Outlook at Raymond James Conference
02:05am, Monday, 09'th Mar 2026
CareDx (NASDAQ: CDNA) executives outlined the company's transplant-focused strategy, recent financial performance, and 2026 priorities during remarks at the Raymond James Institutional Investor Confer
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 27'th Feb 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA), — The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of c
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
01:27am, Wednesday, 25'th Feb 2026
CareDx, Inc. (CDNA) Q4 2025 Earnings Call Transcript
CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say
09:00pm, Tuesday, 24'th Feb 2026
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Stree
CareDx (CDNA) Q4 Earnings Miss Estimates
08:31pm, Tuesday, 24'th Feb 2026
CareDx (CDNA) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.18 per share a year ago.
CareDx Announces Appointment of Keith Kennedy as Chief Operating Officer and Chief Financial Officer
05:15pm, Tuesday, 24'th Feb 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Announces Fourth Quarter and Full Year 2025 Financial Results
04:01pm, Tuesday, 24'th Feb 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
Comparing CareDx (NASDAQ:CDNA) and Elevance Health (NYSE:ELV)
01:13am, Tuesday, 24'th Feb 2026
CareDx (NASDAQ: CDNA - Get Free Report) and Elevance Health (NYSE: ELV - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the
Thrivent Financial for Lutherans Cuts Holdings in CareDx, Inc. $CDNA
03:20am, Friday, 20'th Feb 2026
Thrivent Financial for Lutherans cut its holdings in CareDx, Inc. (NASDAQ: CDNA) by 75.4% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
08:00am, Wednesday, 18'th Feb 2026
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clini
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
12:35pm, Monday, 16'th Feb 2026
CDNA shares climb after AlloHeme data show early AML/MDS relapse detection, backing its Transplant+ expansion into cell therapy markets.
Baron Discovery Fund Q4 2025: Winners, Laggards, Buys & Sells
06:08pm, Sunday, 15'th Feb 2026
In the fourth quarter of 2025, the Baron Discovery Fund returned 0.19% (Institutional Shares), trailing the Russell 2000 Growth Index by 1.03%. In these periods, low quality (high debt and poor profit
